INSM - インスメッド (Insmed Inc.) インスメッド

 INSMのチャート


 INSMの企業情報

symbol INSM
会社名 Insmed Inc (インスメッド)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 インスメッド(Insmed Incorporated)は希少疾患セグメント患者の治療法の開発・商品化を通じて運営するバイオ医薬品会社である。リード製品候補は、マイコバクテリウム・アビウム複合体(MAC)によって引き起こされる治療不応性非結核性マイコバクテリア(NTM)肺疾患の成人患者のための後期段階にある吸入用LAI(ARIKAYCE)、または吸入用リポソームアミカシンである。その初期段階のパイプラインには、メチシリン耐性黄色ブドウ球菌およびNTMを含む、満たされていない医療ニーズの複数のまれな疾患で同社が評価している前臨床化合物が含まれる。初期の臨床段階のパイプラインにはINS1007とINS1009が含まれる。INS1007は、ジペプチジルペプチダーゼ1の経口可逆阻害剤である。INS1009は、肺動脈性高血圧症を含む稀な肺疾患のための差別化された製品プロファイルを提供し得るトレプロスチニルプロドラッグの吸入ナノ粒子製剤である。同社はINS1009の第I相試験を完了した。   インスメッドは、米国のバイオ医薬品メ―カ―。肺疾患の患者向けの吸入治療法を開発し、商品化する。主力製品候補は、肺感染症の吸入抗生物質治療薬「ARIKAYCE(吸入用のリポソ―ム性アミカシン)」である。非結核性抗酸菌症(NTM)による肺感染患者による第2相試験と、緑膿菌の肺感染を伴う嚢胞性線維症(CF)患者による第3相臨床試験を完了した。   
本社所在地 10 Finderne Avenue Building 10 Bridgewater NJ 08807 USA
代表者氏名 William H. Lewis ウィリアムH.ルイス
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 908-977-9900
設立年月日 36465
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 214人
url www.insmed.com
nasdaq_url https://www.nasdaq.com/symbol/insm
adr_tso
EBITDA EBITDA(百万ドル) -241.92400
終値(lastsale) 16.93
時価総額(marketcap) 1304301725.94
時価総額 時価総額(百万ドル) 1264.24
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 937.06700
当期純利益 当期純利益(百万ドル) -255.52400
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Insmed Incorporated revenues was not reported. Net loss increased 77% to $145M. Higher net loss reflects General and Administrative - other increase from $59K to $62.1M (expense) Research and development -other increase of 83% to $61.2M (expense) Interest expense increase from $3M to $12.1M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.32 to -$1.89.

 INSMのテクニカル分析


 INSMのニュース

   Insmed "Unbreakable" by ROOF Studio  2021/01/14 15:43:00 Stash
The team at ROOF Studio in New York engage their talents for hyper-detailed worlds and characters to elevate this film designed to raise awareness of NTM Lung Disease for biopharmaceutical brand Insmed thru agency AREA 23.
   Insmed to Present at the 39th Annual J.P. Morgan Healthcare Conference  2021/01/05 13:00:00 PR Newswire
BRIDGEWATER, N.J., Jan. 5, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the virtual 39th Annual J.P. Morgan…
   Insmed Initiates Frontline Clinical Trial Program for ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with MAC Lung Disease  2021/01/04 13:00:00 PR Newswire
/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare…
   Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)  2020/12/04 13:00:00 PR Newswire
BRIDGEWATER, N.J., Dec. 4, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to seven new employees. In accordance…
   Insmed to Present at the Evercore ISI 3rd Annual HealthCONx Conference  2020/11/24 13:00:00 PR Newswire
BRIDGEWATER, N.J., Nov. 24, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the virtual Evercore ISI 3rd Annual…
   Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)  2020/12/04 13:00:00 PR Newswire
BRIDGEWATER, N.J., Dec. 4, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to seven new employees. In accordance…
   Insmed to Present at the Evercore ISI 3rd Annual HealthCONx Conference  2020/11/24 13:00:00 PR Newswire
BRIDGEWATER, N.J., Nov. 24, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the virtual Evercore ISI 3rd Annual…
   The Daily Biotech Pulse: Kazia Jumps On Data Readout, Clinical Hold On Cellectis' Blood Cancer Study Lifted  2020/11/18 12:29:45 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 17) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) ALX Oncology Holdings Inc (NASDAQ: ALXO ) (announced an oncology collaboration with Zymeworks Inc (NYSE: ZYME )) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Biodesix Inc (NASDAQ: BDSX ) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN C4 Therapeutics Inc (NASDAQ: CCCC ) Champions Oncology Inc (NASDAQ: CSBR ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Edwards Lifesciences Corp (NYSE: EW ) Generation Bio Co (NASDAQ: GBIO ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Immunovant Inc (NASDAQ: IMVT ) Infinity Pharmaceuticals Inc. (NASDAQ: INFI ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Insmed Incorporated (NASDAQ: INSM ) Keros Therapeutics Inc (NASDAQ: KROS ) Kymera Therapeutics Inc (NASDAQ: KYMR ) LeMaitre Vascular Inc (NASDAQ: LMAT ) NeoGenomics, Inc. (NASDAQ: NEO ) Neuronetics Inc (NASDAQ: STIM ) Outset Medical Inc (NASDAQ: OM ) Prelude Therapeutics Inc (NASDAQ: PRL ) PTC Therapeutics, Inc.
   This Is What Hedge Funds Bought And Sold In Q3: Complete 13F Summary  2020/11/17 03:20:00 Zero Hedge
This Is What Hedge Funds Bought And Sold In Q3: Complete 13F Summary Tyler Durden Mon, 11/16/2020 - 22:20 While we live in a time when the holdings of the top 20 Robinhood "investors" have far more information value for markets and other traders than a glimpse into what hedge funds are doing, not in the least because retail investors are outperforming both the S&P500 and hedge funds 10-to-1… ... unfortunately there is still no regulatory requirement for even superstar retail investors to disclose their holdings, which is why we have to be satisfied with the quarterly 13-F publication spectacle, which just concluded today, and which revealed that even as tech stocks suffered two correction shakeouts since early September, hedge funds mostly stuck with the "safety" of tech stocks during the third quarter heading into the election, even as some hedge funds trimmed Amazon.com as the dominant e-commerce platform thrived amid a pandemic-fueled surge in online shopping, while others sold Netflix Courtesy of Bloomberg, below is a snapshot of what some of the most prominent tech stock additions as disclosed by today's barrage of 13F filings: Coatue Management doubled its holdings of Tesla in the three months ended Sept. 30, making the electric-vehicle maker its second-biggest publicly disclosed holding.
   Insmed Receives Priority Medicines (PRIME) Designation from European Medicines Agency (EMA) for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE)  2020/11/13 13:00:00 PR Newswire
BRIDGEWATER, N.J., Nov. 13, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that the European Medicines Agency (EMA) has granted Priority Medicines…
   Insmed to Present at the Evercore ISI 3rd Annual HealthCONx Conference  2020/11/24 13:00:00 PR Newswire
BRIDGEWATER, N.J., Nov. 24, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the virtual Evercore ISI 3rd Annual…
   The Daily Biotech Pulse: Kazia Jumps On Data Readout, Clinical Hold On Cellectis' Blood Cancer Study Lifted  2020/11/18 12:29:45 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 17) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) ALX Oncology Holdings Inc (NASDAQ: ALXO ) (announced an oncology collaboration with Zymeworks Inc (NYSE: ZYME )) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Biodesix Inc (NASDAQ: BDSX ) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN C4 Therapeutics Inc (NASDAQ: CCCC ) Champions Oncology Inc (NASDAQ: CSBR ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Edwards Lifesciences Corp (NYSE: EW ) Generation Bio Co (NASDAQ: GBIO ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Immunovant Inc (NASDAQ: IMVT ) Infinity Pharmaceuticals Inc. (NASDAQ: INFI ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Insmed Incorporated (NASDAQ: INSM ) Keros Therapeutics Inc (NASDAQ: KROS ) Kymera Therapeutics Inc (NASDAQ: KYMR ) LeMaitre Vascular Inc (NASDAQ: LMAT ) NeoGenomics, Inc. (NASDAQ: NEO ) Neuronetics Inc (NASDAQ: STIM ) Outset Medical Inc (NASDAQ: OM ) Prelude Therapeutics Inc (NASDAQ: PRL ) PTC Therapeutics, Inc.
   This Is What Hedge Funds Bought And Sold In Q3: Complete 13F Summary  2020/11/17 03:20:00 Zero Hedge
This Is What Hedge Funds Bought And Sold In Q3: Complete 13F Summary Tyler Durden Mon, 11/16/2020 - 22:20 While we live in a time when the holdings of the top 20 Robinhood "investors" have far more information value for markets and other traders than a glimpse into what hedge funds are doing, not in the least because retail investors are outperforming both the S&P500 and hedge funds 10-to-1… ... unfortunately there is still no regulatory requirement for even superstar retail investors to disclose their holdings, which is why we have to be satisfied with the quarterly 13-F publication spectacle, which just concluded today, and which revealed that even as tech stocks suffered two correction shakeouts since early September, hedge funds mostly stuck with the "safety" of tech stocks during the third quarter heading into the election, even as some hedge funds trimmed Amazon.com as the dominant e-commerce platform thrived amid a pandemic-fueled surge in online shopping, while others sold Netflix Courtesy of Bloomberg, below is a snapshot of what some of the most prominent tech stock additions as disclosed by today's barrage of 13F filings: Coatue Management doubled its holdings of Tesla in the three months ended Sept. 30, making the electric-vehicle maker its second-biggest publicly disclosed holding.
   Insmed Receives Priority Medicines (PRIME) Designation from European Medicines Agency (EMA) for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE)  2020/11/13 13:00:00 PR Newswire
BRIDGEWATER, N.J., Nov. 13, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that the European Medicines Agency (EMA) has granted Priority Medicines…
   LAMIRA®, an eFlow® Technology nebuliser, is the first and only device to deliver Insmed's ARIKAYCE® Liposomal 590 mg Nebuliser Dispersion in the European Union  2020/11/02 15:00:00 PR Newswire
STARNBERG, Germany, Nov. 2, 2020 /PRNewswire/ -- PARI Pharma GmbH, a company focused on the development, manufacturing and commercialisation of advanced aerosol delivery systems based on eFlow Technology, announces the issue of the CE declaration of conformity for its optimised eFlow…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 インスメッド INSM Insmed Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)